The findings indicate that interventions that leverage physician relationships may assist with increasing uptake of new, high-value cancer treatments in place of low-value therapies.
A study published Friday in JAMA Network Open found that peer influence factored heavily into whether oncologists decided to eventually adopt bevacizumab for their patients.
The findings indicate that interventions that leverage physician relationships may assist with increasing uptake of new, high-value cancer treatments in place of low-value therapies, the authors said.
The study took place at the time when only the reference product, Avastin, was available. The first biosimilar bevacizumab, Mvasi, became available in the United States in 2017.
Researchers examined adoption of bevacizumab in 2007 to 2010 among oncologists who had not prescribed the drug in 2005 to 2006.
These oncologists who were associated with fellow oncologists who did use bevacizumab in those years had increased use of the drug in 2007 to 2010.
The cohort study took place in 51 randomly selected hospital referral regions in the United States. Participants were 44,012 fee-for-service Medicare beneficiaries aged 65 years or older with cancers of the colorectum, lung, breast, kidney, brain, or ovary treated by 3261 oncologists in 2005 to 2010.
Data were analyzed in 2017 to 2018.
Among patients treated with chemotherapy during 2007 to 2010 by an oncologist who had not treated patients with the biologic in 2005 to 2006, models (adjusted for patient and physician characteristics and physician, practice, and community random effects) assessed the association of bevacizumab use with rates of use among connected physicians in 2005 to 2006. Of the 44,012, 34,750 patients were treated with chemotherapy in 2005 to 2006 in the 51 hospital referral regions.
Among 9262 patients treated in 2007 to 2010 by 829 physicians whose patients did not use bevacizumab in 2005 to 2006, 3654 (39.5%) were aged 75 years or older and 6227 (67.2%) were female.
The rate of bevacizumab use relative to other chemotherapy in 2007 to 2010 by tertile of use among their physician’s peers in 2005 to 2006 was 10.0%, 9.5%, and 13.6%, respectively. For all patients receiving chemotherapy, the receipt of bevacizumab was less than 4.4%, 4.4% to 6.2%, and more than 6.2%, respectively.
After adjustment, use of bevacizumab in 2007 to 2010 was greater among physicians in communities with the highest rates of bevacizumab use in 2005 to 2006 compared with those whose peers were in the lowest tertile of bevacizumab use in 2005 to 2006 (adjusted odds ratio, 1.64; 95% CI, 1.20-2.25).
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.